NIH Funding Opportunities

Subscribe to NIH Funding Opportunities feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 5 hours 37 min ago

NIH Announces New Centralized Notifications for Unfunded Applications

Thu, 08/22/2019 - 13:13
Notice NOT-OD-19-133 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Request for Information (RFI): Strategies to Support Acquisition and Use of Biospecimens for Research on Sepsis in Humans

Thu, 08/22/2019 - 02:14
Notice NOT-GM-19-057 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed)

Tue, 08/20/2019 - 13:05
Funding Opportunity PAR-19-351 from the NIH Guide for Grants and Contracts. The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and Developmental Research Grant (R21) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R21 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.
Categories: Science RSS Feeds

NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)

Fri, 08/16/2019 - 13:43
Funding Opportunity PAR-19-349 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.
Categories: Science RSS Feeds

Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)

Fri, 08/16/2019 - 13:35
Funding Opportunity PAR-19-346 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.
Categories: Science RSS Feeds

Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 Clinical Trial Not Allowed)

Fri, 08/16/2019 - 13:35
Funding Opportunity PAR-19-347 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.
Categories: Science RSS Feeds

NIDA Program Project Grant Applications (P01 Clinical Trial Optional)

Fri, 08/16/2019 - 10:25
Funding Opportunity PAR-19-345 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA.
Categories: Science RSS Feeds

Notice of Change to Other Attachments in RFA-AI-19-045 "HIV/AIDS Clinical Trials Units (UM1 Clinical Trial Required)"

Fri, 08/16/2019 - 08:39
Notice NOT-AI-19-066 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)

Fri, 08/16/2019 - 02:10
Funding Opportunity PAR-19-348 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.
Categories: Science RSS Feeds

Pages